000163360 001__ 163360
000163360 005__ 20240918164038.0
000163360 0247_ $$2doi$$a10.3390/jpm11101030
000163360 0247_ $$2pmid$$apmid:34683174
000163360 0247_ $$2pmc$$apmc:PMC8539098
000163360 0247_ $$2altmetric$$aaltmetric:115694171
000163360 037__ $$aDZNE-2022-00123
000163360 041__ $$aEnglish
000163360 082__ $$a610
000163360 1001_ $$0P:(DE-HGF)0$$aDehestani, Mohammad$$b0
000163360 245__ $$aPolygenic Risk Scores Contribute to Personalized Medicine of Parkinson's Disease.
000163360 260__ $$aBasel$$bMDPI$$c2021
000163360 3367_ $$2DRIVER$$aarticle
000163360 3367_ $$2DataCite$$aOutput Types/Journal article
000163360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726662709_5389$$xReview Article
000163360 3367_ $$2BibTeX$$aARTICLE
000163360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163360 3367_ $$00$$2EndNote$$aJournal Article
000163360 500__ $$aCC BY
000163360 520__ $$aParkinson's disease (PD) is the second most common neurodegenerative disorder characterized by the loss of dopaminergic neurons. The vast majority of PD patients develop the disease sporadically and it is assumed that the cause lies in polygenic and environmental components. The overall polygenic risk is the result of a large number of common low-risk variants discovered by large genome-wide association studies (GWAS). Polygenic risk scores (PRS), generated by compiling genome-wide significant variants, are a useful prognostic tool that quantifies the cumulative effect of genetic risk in a patient and in this way helps to identify high-risk patients. Although there are limitations to the construction and application of PRS, such as considerations of limited genetic underpinning of diseases explained by SNPs and generalizability of PRS to other populations, this personalized risk prediction could make a promising contribution to stratified medicine and tailored therapeutic interventions in the future.
000163360 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163360 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163360 650_7 $$2Other$$aParkinson’s disease
000163360 650_7 $$2Other$$apersonalized medicine
000163360 650_7 $$2Other$$apolygenic risk scores
000163360 7001_ $$0P:(DE-2719)9001971$$aLiu, Hui$$b1$$udzne
000163360 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b2$$eLast author$$udzne
000163360 770__ $$aOmics Approaches and Personalized Medicine in Neurodegenerative Diseases
000163360 773__ $$0PERI:(DE-600)2662248-8$$a10.3390/jpm11101030$$gVol. 11, no. 10, p. 1030 -$$n10$$p1030$$tJournal of Personalized Medicine$$v11$$x2075-4426$$y2021
000163360 8564_ $$uhttps://pub.dzne.de/record/163360/files/DZNE-2022-00123.pdf$$yOpenAccess
000163360 8564_ $$uhttps://pub.dzne.de/record/163360/files/DZNE-2022-00123.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163360 909CO $$ooai:pub.dzne.de:163360$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000163360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001971$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163360 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163360 9141_ $$y2021
000163360 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-06-15
000163360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-06-15
000163360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-06-15
000163360 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-06-15
000163360 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163360 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-06-15
000163360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PERS MED : 2021$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-08-24T10:22:54Z
000163360 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-08-24T10:22:54Z
000163360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-08-24T10:22:54Z
000163360 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-23
000163360 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-23
000163360 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000163360 9201_ $$0I:(DE-2719)6000018$$kTübingen common$$lTübingen common$$x1
000163360 980__ $$ajournal
000163360 980__ $$aVDB
000163360 980__ $$aI:(DE-2719)1210000
000163360 980__ $$aI:(DE-2719)6000018
000163360 980__ $$aUNRESTRICTED
000163360 9801_ $$aFullTexts